Latest News First Patient Dosed in Senhwa’s International Study Pairing CX-5461 with PD-1 Inhibitor, Marking a Key Advance for MSS Colorectal Cancer Sep 07 2026 Latest News Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027 Aug 25 2026 Latest News Senhwa’s CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research Aug 12 2026 Media Coverage Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research Aug 12 2026 Media Coverage GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million Jul 14 2026 Media Coverage Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development Apr 14 2026 Publications The UVA-induced single-base mutational signature of CX-5461 in human cells Aug 28 2026 Publications The G-quadruplex ligand CX-5461 inhibits laryngeal cancer via inducing immunogenic cell death and remodeling the tumor immune microenvironment Aug 19 2026 Publications G-quadruplex DNA reprograms the photochemistry of CX-5461 toward radical-driven anticancer activity Aug 12 2026